CL2013000033A1 - Compuestos derivados de tetrahidro-pirido-pirimidina, moduladores de pi3k; composicion farmaceutica que los comprende; combinacion farmaceutica; proceso de preparacion de estos; y su uso en el tratamiento de una enfermedad inflamatoria, autoinmune, cardiovascular, neurodegenerativa, metabolica, oncologica, entre otras - Google Patents

Compuestos derivados de tetrahidro-pirido-pirimidina, moduladores de pi3k; composicion farmaceutica que los comprende; combinacion farmaceutica; proceso de preparacion de estos; y su uso en el tratamiento de una enfermedad inflamatoria, autoinmune, cardiovascular, neurodegenerativa, metabolica, oncologica, entre otras

Info

Publication number
CL2013000033A1
CL2013000033A1 CL2013000033A CL2013000033A CL2013000033A1 CL 2013000033 A1 CL2013000033 A1 CL 2013000033A1 CL 2013000033 A CL2013000033 A CL 2013000033A CL 2013000033 A CL2013000033 A CL 2013000033A CL 2013000033 A1 CL2013000033 A1 CL 2013000033A1
Authority
CL
Chile
Prior art keywords
pyrido
tetrahydro
autoimmune
neurodegenerative
cardiovascular
Prior art date
Application number
CL2013000033A
Other languages
English (en)
Inventor
Graham Cooke Nigel
Fernandes Gomes Dos Santos Paulo
Graveleau Nadege
Hebach Christina
Hogenauer Klemens
Hollingworth Gregory
Baxter Smith Alexander
Soldermann Nicolas
Stowasser Frank
Strang Ross
Tufilli Nicola
Von Matt Anette
Wolf Romain
Zecri Frederic
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2013000033A1 publication Critical patent/CL2013000033A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Compuestos derivados de tetrahidro-pirido-pirimidina, moduladores de PI3K; proceso de preparación; composición farmacéutica; combinación farmacéutica; y su uso en enfermedades como artritis reumatoides. Púrpura trombocitopénica; anemia hemolítica autoinmune, rechazo de trasplante, entre otras.
CL2013000033A 2010-07-06 2013-01-04 Compuestos derivados de tetrahidro-pirido-pirimidina, moduladores de pi3k; composicion farmaceutica que los comprende; combinacion farmaceutica; proceso de preparacion de estos; y su uso en el tratamiento de una enfermedad inflamatoria, autoinmune, cardiovascular, neurodegenerativa, metabolica, oncologica, entre otras CL2013000033A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36158910P 2010-07-06 2010-07-06

Publications (1)

Publication Number Publication Date
CL2013000033A1 true CL2013000033A1 (es) 2013-05-10

Family

ID=44532774

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013000033A CL2013000033A1 (es) 2010-07-06 2013-01-04 Compuestos derivados de tetrahidro-pirido-pirimidina, moduladores de pi3k; composicion farmaceutica que los comprende; combinacion farmaceutica; proceso de preparacion de estos; y su uso en el tratamiento de una enfermedad inflamatoria, autoinmune, cardiovascular, neurodegenerativa, metabolica, oncologica, entre otras

Country Status (39)

Country Link
US (10) US8653092B2 (es)
EP (1) EP2590974B1 (es)
JP (1) JP5770842B2 (es)
KR (1) KR101560066B1 (es)
CN (1) CN102971317B (es)
AR (3) AR084970A1 (es)
AU (1) AU2011275777C1 (es)
BR (1) BR112013000275B1 (es)
CA (1) CA2802132C (es)
CL (1) CL2013000033A1 (es)
CO (1) CO6670566A2 (es)
CR (1) CR20130004A (es)
DK (1) DK2590974T3 (es)
DO (1) DOP2013000027A (es)
EA (1) EA024123B1 (es)
EC (1) ECSP13012420A (es)
ES (1) ES2494718T3 (es)
GT (1) GT201300009A (es)
HR (1) HRP20140778T1 (es)
IL (1) IL223795A (es)
JO (1) JO2939B1 (es)
MA (1) MA34361B1 (es)
MX (1) MX2012015088A (es)
MY (1) MY166026A (es)
NI (1) NI201300002A (es)
NZ (1) NZ604302A (es)
PE (1) PE20130650A1 (es)
PH (1) PH12013500031A1 (es)
PL (1) PL2590974T3 (es)
PT (1) PT2590974E (es)
RS (1) RS53490B1 (es)
SG (1) SG186187A1 (es)
SI (1) SI2590974T1 (es)
TN (1) TN2012000578A1 (es)
TW (1) TWI534145B (es)
UA (1) UA112517C2 (es)
UY (1) UY33486A (es)
WO (1) WO2012004299A1 (es)
ZA (1) ZA201209117B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8759362B2 (en) * 2008-10-24 2014-06-24 Purdue Pharma L.P. Bicycloheteroaryl compounds and their use as TRPV1 ligands
UA112517C2 (uk) 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
JO3733B1 (ar) 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
KR20140025530A (ko) 2011-06-27 2014-03-04 노파르티스 아게 테트라히드로-피리도-피리미딘 유도체의 고체 형태 및 염
ES2661510T3 (es) * 2011-12-15 2018-04-02 Novartis Ag Uso de inhibidores de la actividad o función de PI3K
PT2794600T (pt) 2011-12-22 2018-03-13 Novartis Ag Derivados de 2,3-di-hidro-benzo[1,4]oxazina e compostos relacionados como inibidores de fosfoinositídeo-3-cinase (pi3k) para o tratamento de, por exemplo, artrite reumatoide
JP6434416B2 (ja) 2012-11-08 2018-12-05 ライゼン・ファーマシューティカルズ・エスアー ＰＤＥ４阻害剤とＰＩ３δ阻害剤または二重ＰＩ３δ−γキナーゼ阻害剤とを含有する薬学的組成物
CA2891009A1 (en) * 2012-11-16 2014-05-22 Merck Sharp & Dohme Corp. Purine inhibitors of human phosphatidylinositol 3-kinase delta
CA2891013A1 (en) 2012-11-16 2014-05-22 Abdelghani Abe Achab Purine inhibitors of human phosphatidylinositol 3-kinase delta
EP3251673A1 (en) 2012-12-13 2017-12-06 IP Gesellschaft für Management mbH Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer
UY35675A (es) 2013-07-24 2015-02-27 Novartis Ag Derivados sustituidos de quinazolin-4-ona
WO2015162584A1 (en) 2014-04-24 2015-10-29 Novartis Ag Crystalline forms of the sulfate salt of n-[5-(3-imidazol-1-yl-4-methanesulfonyl-phenyl)-4-methyl-thiazol-2-yl]-acetamide
GB201506786D0 (en) * 2015-04-21 2015-06-03 Ucb Biopharma Sprl Therapeutic use
CN107624113B (zh) * 2015-05-04 2020-10-23 豪夫迈·罗氏有限公司 作为HBsAg (HBV 表面抗原)和HBV DNA 生成的抑制剂用于治疗乙型肝炎病毒感染的四氢吡啶并嘧啶和四氢吡啶并吡啶类化合物
MX2018006767A (es) 2015-12-04 2019-03-14 Novartis Ag Composiciones y metodos para oncologia inmunologica.
WO2017118965A1 (en) * 2016-02-10 2017-07-13 Novartis Ag Use of inhibitors of the activity or function of pi3k for the treatment of primary sjögren's syndrome
BR112019018124A2 (pt) 2017-03-22 2020-04-07 Intellia Therapeutics Inc composições e métodos para imunooncologia
EP3630116B1 (en) 2017-05-26 2024-05-01 The Board Of Regents Of The University Of Texas System Tetrahydropyrido[4,3-d]pyrimidine inhibitors of atr kinase
HUE066043T2 (hu) 2017-07-13 2024-07-28 Univ Texas A TR kináz beterociklusos inhibitorai
US10800774B2 (en) 2017-08-17 2020-10-13 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of ATR kinase
JP7341156B2 (ja) 2018-03-16 2023-09-08 ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム Ａｔｒキナーゼの複素環式阻害剤
CN114315826B (zh) * 2021-11-30 2023-05-16 西安交通大学 一种吡啶并嘧啶类化合物及其应用
KR20230160977A (ko) 2022-05-17 2023-11-27 에이치앤오바이오시스(주) 항암 치료에 사용되는 5종 이상의 생약 추출물

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1197466B (de) 1962-03-22 1965-07-29 Thomae Gmbh Dr K Verfahren zur Herstellung von neuen 5, 6, 7, 8-Tetrahydropyrido-[4, 3-d]pyrimidinen
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
EP0100172B1 (en) 1982-07-23 1987-08-12 Imperial Chemical Industries Plc Amide derivatives
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US5010099A (en) 1989-08-11 1991-04-23 Harbor Branch Oceanographic Institution, Inc. Discodermolide compounds, compositions containing same and method of preparation and use
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
TW225528B (es) 1992-04-03 1994-06-21 Ciba Geigy Ag
US5300645A (en) 1993-04-14 1994-04-05 Eli Lilly And Company Tetrahydro-pyrido-indole
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
EP2163546B1 (en) 1995-03-30 2016-06-01 Pfizer Products Inc. Quinazoline derivatives
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
TR199800012T1 (xx) 1995-07-06 1998-04-21 Novartis Ag Piroloprimidinler ve preparasyon i�in tatbikler.
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
DE69710712T3 (de) 1996-04-12 2010-12-23 Warner-Lambert Co. Llc Umkehrbare inhibitoren von tyrosin kinasen
CA2258548C (en) 1996-06-24 2005-07-26 Pfizer Inc. Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
NZ334821A (en) 1996-08-30 2000-12-22 Novartis Ag Method for producing epothilones
ATE247724T1 (de) 1996-09-06 2003-09-15 Obducat Ab Verfahren für das anisotrope ätzen von strukturen in leitende materialien
AU4342997A (en) 1996-09-13 1998-04-02 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the reatment of hyperproliferative skin disorders
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
DK0941227T5 (da) 1996-11-18 2009-10-05 Biotechnolog Forschung Gmbh Epothilon D, dens fremstilling samt dens anvendelse som cytostatisk middel og som plantebeskyttelsesmiddel
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
US5939421A (en) * 1997-07-01 1999-08-17 Signal Pharmaceuticals, Inc. Quinazoline analogs and related compounds and methods for treating inflammatory conditions
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
CA2322157C (en) 1998-02-25 2012-05-29 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
NZ511722A (en) 1998-11-20 2004-05-28 Kosan Biosciences Inc Recombinant methods and materials for producing epothilone and epothilone derivatives
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
RU2329263C2 (ru) 2000-11-07 2008-07-20 Новартис Аг Производные имида индолилмалеиновой кислоты как ингибиторы протеинкиназы с
AR035885A1 (es) 2001-05-14 2004-07-21 Novartis Ag Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
AR039209A1 (es) 2002-04-03 2005-02-09 Novartis Ag Derivados de indolilmaleimida
MXPA05006133A (es) 2002-12-09 2006-03-09 Univ Texas Metodos para inhibir selectivamente la tirosino quinasa jano 3 (jak3).
RU2329265C2 (ru) 2002-12-27 2008-07-20 Институто Ди Ричерке Ди Биолоджиа Молеколаре П.Анджелетти Спа ТЕТРАГИДРО-4Н-ПИРИДО[1,2-а]ПИРИМИДИНЫ И РОДСТВЕННЫЕ СОЕДИНЕНИЯ, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ВИЧ-ИНТЕГРАЗЫ
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
ZA200602666B (en) 2004-01-12 2007-09-26 Cytopia Res Pty Ltd Selective kinase inhibitors
CA2553969A1 (en) * 2004-01-23 2005-08-04 Amgen Inc. Vanilloid receptor ligands and their use in treatments
SI1761528T1 (sl) 2004-06-11 2008-06-30 Japan Tobacco Inc 5-amino-2,4,7-triokso-3,4,7,8-tetrahidro-2H-pirido(2,3-D)pirimidinski derivati in sorodne spojine za zdravljenje raka
US20060128710A1 (en) 2004-12-09 2006-06-15 Chih-Hung Lee Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof
EP1885369B1 (en) 2005-05-04 2015-09-23 Evotec AG Fused heterocyclic compounds, and compositions and uses thereof
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
CA2682162C (en) * 2007-04-02 2016-05-10 Renovis, Inc. Pyrid-2-yl fused heterocyclic compounds, and compositions and uses thereof
PT2139334E (pt) * 2007-04-17 2013-10-02 Evotec Ag Compostos heterocíclicos fusionados de 2-cianofenilo, e composições e utilizações dos mesmos
WO2009047255A1 (en) 2007-10-09 2009-04-16 Ucb Pharma, S.A. Heterobicyclic compounds as histamine h4-receptor antagonists
EP2231666B1 (en) 2007-12-12 2015-07-29 Rigel Pharmaceuticals, Inc. Carboxamide, sulfonamide and amine compounds for metabolic disorders
US8436005B2 (en) 2008-04-03 2013-05-07 Abbott Laboratories Macrocyclic pyrimidine derivatives
US20120028940A1 (en) 2008-09-16 2012-02-02 Merck Sharp & Dohme Corp. Functionally selective azanitrile alpha-2c adrenoreceptor agonists
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
US8759362B2 (en) 2008-10-24 2014-06-24 Purdue Pharma L.P. Bicycloheteroaryl compounds and their use as TRPV1 ligands
US8546388B2 (en) 2008-10-24 2013-10-01 Purdue Pharma L.P. Heterocyclic TRPV1 receptor ligands
JP2010105951A (ja) 2008-10-29 2010-05-13 Dainippon Sumitomo Pharma Co Ltd ６−アルキル置換テトラヒドロピリド［４，３−ｄ］ピリミジン誘導体
TW201102391A (en) 2009-03-31 2011-01-16 Biogen Idec Inc Certain substituted pyrimidines, pharmaceutical compositions thereof, and methods for their use
WO2010120991A1 (en) 2009-04-17 2010-10-21 Wyeth Llc 5, 6, 7, 8-tetrahydropyrido[4,3-d]pyrimidine compounds, their use as mtor, pi3, and hsmg-1 kinase inhibitors, and their syntheses
US20100280067A1 (en) 2009-04-30 2010-11-04 Pakala Kumara Savithru Sarma Inhibitors of acetyl-coa carboxylase
EP2440559B1 (en) 2009-05-05 2018-01-10 Dana-Farber Cancer Institute, Inc. Egfr inhibitors and methods of treating disorders
EP2434885B1 (en) 2009-05-27 2014-03-26 Merck Sharp & Dohme Corp. Alkoxy tetrahydro-pyridopyrimidine pde10 inhibitors
JP2013032290A (ja) 2009-11-20 2013-02-14 Dainippon Sumitomo Pharma Co Ltd 新規縮合ピリミジン誘導体
CA2786277A1 (en) 2010-01-06 2011-07-14 Joseph P. Errico Methods and compositions of targeted drug development
SA111320200B1 (ar) 2010-02-17 2014-02-16 ديبيوفارم اس ايه مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة
WO2011103715A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Task channel antagonists
EP2569302A1 (en) 2010-05-13 2013-03-20 Amgen, Inc Heteroaryloxyheterocyclyl compounds as pde10 inhibitors
AU2011255218B2 (en) 2010-05-21 2015-03-12 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
UA112517C2 (uk) 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
ES2661510T3 (es) 2011-12-15 2018-04-02 Novartis Ag Uso de inhibidores de la actividad o función de PI3K

Also Published As

Publication number Publication date
MY166026A (en) 2018-05-21
US20180265509A1 (en) 2018-09-20
US20170022199A1 (en) 2017-01-26
BR112013000275B1 (pt) 2020-12-01
ES2494718T3 (es) 2014-09-16
HK1179966A1 (en) 2013-10-11
MX2012015088A (es) 2013-02-12
CA2802132C (en) 2019-02-26
AR118919A2 (es) 2021-11-10
AU2011275777B2 (en) 2014-07-31
UA112517C2 (uk) 2016-09-26
JP5770842B2 (ja) 2015-08-26
AR084970A1 (es) 2013-07-24
CA2802132A1 (en) 2012-01-12
US9499536B2 (en) 2016-11-22
US20140128370A1 (en) 2014-05-08
US20170267678A1 (en) 2017-09-21
US20120065183A1 (en) 2012-03-15
AU2011275777C1 (en) 2015-02-05
US20190040061A1 (en) 2019-02-07
JO2939B1 (en) 2016-03-15
GT201300009A (es) 2015-06-02
PT2590974E (pt) 2014-09-01
KR20130041068A (ko) 2013-04-24
SG186187A1 (en) 2013-01-30
DK2590974T3 (da) 2014-07-28
CN102971317A (zh) 2013-03-13
EP2590974B1 (en) 2014-05-21
US20220267318A1 (en) 2022-08-25
HRP20140778T1 (hr) 2014-09-12
MA34361B1 (fr) 2013-07-03
TWI534145B (zh) 2016-05-21
RS53490B1 (sr) 2015-02-27
CO6670566A2 (es) 2013-05-15
IL223795A (en) 2015-11-30
WO2012004299A1 (en) 2012-01-12
AR115927A2 (es) 2021-03-10
NZ604302A (en) 2014-11-28
US8653092B2 (en) 2014-02-18
BR112013000275A2 (pt) 2016-06-14
PL2590974T3 (pl) 2014-10-31
EP2590974A1 (en) 2013-05-15
NI201300002A (es) 2013-04-15
UY33486A (es) 2012-02-29
AU2011275777A1 (en) 2012-12-20
CR20130004A (es) 2013-04-17
TN2012000578A1 (en) 2014-04-01
KR101560066B1 (ko) 2015-10-13
TW201206930A (en) 2012-02-16
PE20130650A1 (es) 2013-06-15
SI2590974T1 (sl) 2014-08-29
JP2013535411A (ja) 2013-09-12
DOP2013000027A (es) 2013-09-30
CN102971317B (zh) 2016-01-20
PH12013500031A1 (en) 2015-04-15
US20190218217A1 (en) 2019-07-18
US20200392132A1 (en) 2020-12-17
EA201291317A1 (ru) 2013-05-30
ZA201209117B (en) 2013-09-25
EA024123B1 (ru) 2016-08-31
ECSP13012420A (es) 2013-03-28
US20250059181A1 (en) 2025-02-20

Similar Documents

Publication Publication Date Title
CL2013000033A1 (es) Compuestos derivados de tetrahidro-pirido-pirimidina, moduladores de pi3k; composicion farmaceutica que los comprende; combinacion farmaceutica; proceso de preparacion de estos; y su uso en el tratamiento de una enfermedad inflamatoria, autoinmune, cardiovascular, neurodegenerativa, metabolica, oncologica, entre otras
MX379193B (es) Composiciones en solucion solida y su uso en inflamacion cronica.
CL2014003462A1 (es) Uso de compuestos aminotriazolopiridinas sustituidos, en el tratamiento de afecciones inflamatorias, autoinmunitarias, proliferativas, alergias, rechazo de trasplantes, entre otras; composicion farmaceutica que los comprende; combinacion farmaceutica.
CR20140493A (es) Compuestos novedosos
CL2013000603A1 (es) Compuestos derivados de quinolina y quinoxalina, inhibidores pi3k; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad inflamatoria, autoinmune, cardiovascular, neurodegenerativa, metabolica, oncologica, nocicenociceptiva y oftalmica.
PH12015501244A1 (en) Modulators of the retinoid-related orphan receptor gamma (ror-gamma) for use in the treatment of autoimmune and inflammatory diseases
CL2016002310A1 (es) Nuevos compuestos bicíclicos.
CL2015000256A1 (es) Compuestos heteroaromáticos, inhibidores de btk, composicion farmaceutica que los comprende y uso en enfermedades tales como artritis reumatoide, lupus, entre otras.
NI201400079A (es) Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CL2015001231A1 (es) Compuestos heterocíclicos sustituidos con amida; composicion farmaceutica; útiles en el tratamiento de una enfermedad inflamatoria o autoinmune.
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
UY34779A (es) Anticuerpos anti-il-23 y composiciones farmacéuticas que los contienen
JO3154B1 (ar) عوامل مضادة لـ trpv4
CL2015002386A1 (es) Nuevos octahidro-pirrolo[3,4-c)-pirrol y -piridina-fenilo.
UA117008C2 (uk) IN VITRO ТРАНСКРИБОВАНА мРНК ТА КОМПОЗИЦІЯ, ЩО ЇЇ МІСТИТЬ, ДЛЯ ЗАСТОСУВАННЯ В ЛІКУВАННІ МУКОВІСЦИДОЗУ В ССАВЦЯ
CL2013003019A1 (es) Compuestos derivados de benzotiazol; composicion farmaceutica que los comprende; y su uso en el tratamiento del vih.
CL2013001754A1 (es) Compuestos derivados de enonas triciclicas y tetraciclicas de pirazolilo y pirimidinilo; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades inflamatorias.
CR20140200A (es) Formas solidas de 3-(5-amino-2-metil-4-oxo-ah-quinazolin-3-il)-piperidin-2,6-diona, y sus composiciones farmaceuticas y sus usos
SV2014004771A (es) Nuevos derivados fosfatos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
DOP2016000014A (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
UY34185A (es) ?partículas cristalinas recubiertas con micelas de copolímeros, composiciones, proceso de preparación de dichas partículas y sus usos?.
CO2017002159A2 (es) Derivados de heterociclilo opcionalmente condensados de pirimidina útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias
EA201591712A1 (ru) Антибиотические композиции на основе цефтолозана
CL2015002030A1 (es) Dihidropirimidinomas bicíclicas sustituidas y su uso como inhibidores de la actividad de elastasa neutrofílica
CO7461129A2 (es) Beta-glucosidasa de magnaporthe grisea